Sortilin as a regulator of lipoprotein metabolism

Current Atherosclerosis Reports

Volumn 14, Issue 3, 2012, Pages 211-218

  Strong, Alanna ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Atherosclerotic cardiovascular disease; Genome wide association study; Lipid metabolism; Low density lipoprotein cholesterol; Sort1

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SORTILIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALLELE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE LOCUS; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; METABOLIC REGULATION; NONHUMAN; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SORTILIN GENE;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ATHEROSCLEROSIS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIPID METABOLISM; LIPIDS;

EID: 84861233637     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0248-x     Document Type: Article

References (30)

1. Lloyd-Jones D, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:948-54.
2. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-41.
3. Waters DD, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving lowdensity lipoprotein cholesterol goals. Circulation. 2009;120:28-34.
4. Hobbs HaD. In: Harrison's principles of internal medicine. McGraw Hill; 2007. pp. 2416-29.
5. Kathiresan S, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189-97. (Pubitemid 351171402)
6. Willer CJ, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161-9. (Pubitemid 351171403)
7. Kathiresan S, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41:56-65. This is a genome-wide association study in European populations identifying 10 novel genetic determinants of lipid traits.
8. Teslovich TM, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466;707-13. This is the largest genome-wide association study for lipid traits, and it identified 95 total loci associated with lipid traits, including 59 novel loci. Many of these loci were replicated in non-European populations as well. This study named the SORT1 locus as a genome-wide significant determinant of LDL-C levels and cardiovascular disease risk in European and non-European populations with the lowest P-value in the human genome for LDL-C.
9. Samani NJ, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443-53. (Pubitemid 47204873)
10. Schunkert H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333-8. This large-scale genome-wide association study for cardiovascular disease with 135,000 individuals of European descent identified 13 novel loci for CAD.
11. Qi L, et al. Genetic risk score and risk of myocardial infarction in Hispanics. Circulation. 2011;123;374-80.
12. Zhou L, et al. Genetic variants at newly identified lipid loci are associated with coronary heart disease in a Chinese Han population. PLoS One. 2011;6:e27481.
13. Kathiresan S, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41:334-41. This is a genome-wide association study of cardiovascular disease and early-onset myocardial infarction.
14. Chasman DI, et al. Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ Cardiovasc Genet. 2008;1:21-30.
15. Linsel-Nitschke P, et al. Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis. 2010;208:183-9. This is the first mechanistic study associating elevated Sort1 expression with increased LDL uptake.
16. Nakayama K, et al. Large scale replication analysis of loci associated with lipid concentrations in a Japanese population. J Med Genet. 2009;46:370-4.
17. Musunuru K, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466:714-9. This study identified the causal SNP at the 1p13 locus that confers the expression changes seen with the minor allele and in vivo proof of principles studies showing that Sort1 overexpression reduces plasma cholesterol and VLDL secretion, whereas Sort1 knockdown increases plasma cholesterol and VLDL secretion.
18. Gupta R, et al. Association of common DNA sequence variants at 33 genetic loci with blood lipids in individuals of African ancestry from Jamaica. Hum Genet. 2010;128:557-61.
19. Keebler ME, et al. Association of blood lipids with common DNA sequence variants at 19 genetic loci in the multiethnic United States National Health and Nutrition Examination Survey III. Circ Cardiovasc Genet. 2009;2:238-43.
20. Nielsen MS, et al. The sortilin cytoplasmic tail conveys Golgiendosome transport and binds the VHS domain of the GGA2 sorting protein. EMBO J. 2001;20:2180-90. (Pubitemid 32410588)
21. Nykjaer A, et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature. 2004;427:843-8. (Pubitemid 38297746)
22. Hu F, et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron. 2010;68:654-67. This study shows that SORT1 mediates the lysosomal degradation of progranulin and shows a functional relationship between sortilin and frontotemporal dementia.
23. Navarro V, Vincent JP, Mazella J. Shedding of the luminal domain of the neurotensin receptor-3/sortilin in the HT29 cell line. Biochem Biophys Res Commun. 2002;298:760-4. (Pubitemid 35356805)
24. Evans SF, et al. Neuronal brain-derived neurotrophic factor is synthesized in excess, with levels regulated by sortilin-mediated trafficking and lysosomal degradation. J Biol Chem. 2011;286:29556-67.
25. Nielsen MS, Jacobsen C, Olivecrona G, Gliemann J, Petersen CM. Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase. J Biol Chem. 1999;274:8832-6. (Pubitemid 29164682)
26. Jacobsen L, et al. Activation and functional characterization of the mosaic receptor SorLA/LR11. J Biol Chem. 2001;276:22788-96.
27. Nilsson SK, et al. Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families. J Biol Chem. 2008;283:25920-7.
28. Kjolby M, et al. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab. 2010;12:213-23. This is a mechanistic studies using a SORT-/- mouse that suggest that Sort1 deficiency is associated with reduced plasma cholesterol and reduced VLDL secretion.
29. Ai D, Baez JM, Jiang H, Conlon D, Hernandez-Ono A, Frank-Kamenetsky M, Milstein S, et al. Activation of ER stress and mTORC1 supresses hepatic sortilin-1 levels in obese mice. J Clin Investi. 2012; Apr 2 [Epub ahead of print]. This is a study showing that Sort1 expression is regulated by ER stress and mTOR signaling and demonstrating that elevated Sort1 expression is associated with reductions in VLDL/apoB secretion whereas reduced Sort1 expression is associated with increased VLDL/apoB secretion.
30. Jansen P, et al. Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. Nat Neurosci. 2007;10:1449-57. (Pubitemid 350014687)